Using CAR T cells that target multiple antigens to treat acute myeloid leukemia
Multi-antigen-specific CAR T cells to treat acute myeloid leukemia
This study is testing a new kind of CAR T cell therapy designed to help people with acute myeloid leukemia (AML) by training their immune cells to better recognize and fight the cancer, with the hope of improving treatment success and lowering the risk of the cancer coming back.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11142746 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of CAR T cell therapy that targets multiple antigens to treat acute myeloid leukemia (AML). The approach involves modifying T cells to recognize and attack cancer cells more effectively, especially since AML can vary greatly in its antigen expression. By using a novel system to create and purify these multi-antigen-specific T cells, the research aims to improve treatment outcomes and reduce the chances of cancer relapse. Patients will be monitored for their response to this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have not responded to standard treatments.
Not a fit: Patients with other types of leukemia or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results with CAR T cell therapies targeting single antigens, but this multi-antigen approach is relatively novel and untested.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: James, Scott E — Beckman Research Institute/city of Hope
- Study coordinator: James, Scott E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.